Immunogenicity of Current and Next-Generation Pneumococcal Conjugate Vaccines in Children: Current Challenges and Upcoming Opportunities
Feemster K, Buchwald U, Banniettis N, Joyce J, Velentgas P, Chapman T, Yildirim I. Immunogenicity of Current and Next-Generation Pneumococcal Conjugate Vaccines in Children: Current Challenges and Upcoming Opportunities. Open Forum Infectious Diseases 2024, 11: ofae220. PMID: 38770212, PMCID: PMC11103622, DOI: 10.1093/ofid/ofae220.Peer-Reviewed Original ResearchA Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults
Kao C, Rostad C, Nolan L, Peters E, Kleinhenz J, Sherman J, Tippett A, Shih J, Yildirim I, Agbakoba V, Beresnev T, Ballou C, Kamidani S, Karmali V, Natrajan M, Scherer E, Rouphael N, Anderson E. A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults. The Journal Of Infectious Diseases 2024, jiae148. PMID: 38536442, DOI: 10.1093/infdis/jiae148.Peer-Reviewed Original ResearchHealthy US adultsDouble-blindThird dosePlacebo-Controlled Clinical TrialSystemic reactionsHepatitis E virus vaccineUS adultsHepatitis E vaccinePlacebo groupPlacebo-controlledAdverse eventsE vaccineSecond doseClinical trialsDay 1Immune responseDosePhase 1ImmunogenicityMonthsSafety studiesVaccineInfant mortalityTrialsAdults